9月25日，由紫荆文化集团主办、紫荆杂志社承办的"2025香港国际中医药大会"在香港会议展览中心盛 大启幕。本次大会以"推动中医药高质量走向世界"为主题，汇聚来自中国内地及港澳台地区、东南亚等 国家和地区的近500位专家学者、行业领袖及企业代表，包括20余位院士、国医大师、岐黄学者，以及 超过130家参展机构。漳州片仔癀药业股份有限公司（以下简称"片仔癀公司"；股票代码：600436.SH） 作为中华老字号企业及中医药文化的重要代表受邀参展，携旗下多款核心产品亮相，全面展现片仔癀公 司在传统中医药现代化与国际化进程中的积极探索与成果。 片仔癀公司展区集中展示了包括片仔癀、片仔癀牌安宫牛黄丸、复方片仔癀含片、茵胆平肝胶囊等在内 的经典中成药品，以及化妆品与保健食品系列等大健康领域产品，吸引了众多重要嘉宾、专业观众、行 业专家及媒体前来参观交流、驻足咨询。来访者纷纷对片仔癀公司传承非遗技艺与推动科技创新的成果 表示赞赏，并高度认可片仔癀公司的产品品质与文化内涵。现场洽谈气氛活跃，进一步提升了品牌在粤 港澳大湾区及国际市场的知名度。 1.依托区域优势开拓"出海"新途径 此次参展是片仔癀公司推动中医药国际化、加速品牌 ...

Core Viewpoint - Pianzaihuang, a traditional Chinese medicine brand, is revitalizing its heritage through innovation and modernization, focusing on research breakthroughs and industry expansion to adapt to contemporary consumer needs [1][3]. Historical Background - The origins of Pianzaihuang date back to the late Ming Dynasty when a court physician created a secret formula for treating ailments, which later became widely used by the local population [2]. - The brand evolved into a company in 1999 and was listed on the Shanghai Stock Exchange in 2003, marking the beginning of its modern journey [2]. Research and Development - Pianzaihuang is recognized as a national high-tech enterprise and has established multiple research platforms, focusing on developing new drugs for chronic and difficult diseases [3]. - The company has 18 ongoing research projects and aims to validate traditional medicine through modern scientific methods, with significant achievements in 2024 recognized by awards [3]. Marketing and Consumer Engagement - The company is actively engaging younger consumers through social media platforms like Douyin and Xiaohongshu, using creative content to share the brand's story and benefits [3]. - A Douyin challenge in 2025 garnered significant attention, with 180 million views and nearly 10,000 participants, showcasing the brand's successful outreach [4]. Business Expansion - Pianzaihuang is diversifying its business into cosmetics, daily chemicals, and health foods, creating a comprehensive health industry ecosystem [5]. - The cosmetics line, particularly the Pearl Cream and Pearl Paste, has become a household name in Fujian, with a strategic focus on positioning and branding [5][6]. Product Development - The company has successfully launched several high-revenue products, including the Pearl Cream and various skincare lines, contributing to the growth of domestic cosmetics consumption [6]. - Pianzaihuang is expanding its daily chemical products, initially focusing on oral care, with the Pianzaihuang Toothpaste becoming a popular choice among consumers [6]. Health Food Initiatives - The health food segment includes a variety of product lines, such as tea and dietary supplements, with collaborations to enhance the health benefits of tea [7]. - New herbal drinks and instant products are being introduced to cater to modern consumer preferences, emphasizing the concept of "food as medicine" [7]. Industry Trends - The traditional medicine sector in Zhangzhou is experiencing a renaissance, with Pianzaihuang leading initiatives to modernize and attract younger consumers [8][9]. - The company has opened numerous clinics and health centers, significantly increasing patient visits and enhancing local healthcare access [8]. Financial Performance - In 2024, the combined revenue of 30 traditional brands in Zhangzhou exceeded 10.4 billion, reflecting an overall growth of 11.22% [10].

Core Viewpoint - The article highlights the strategic initiatives of the company in promoting traditional Chinese medicine and health products, focusing on product development, international expansion, and investment in the health industry [4][5][6]. Group 1: Product Development and Market Strategy - The company is committed to enhancing its flagship product, Pianzaihuang, and expanding its product line with significant items such as the compound Pianzaihuang lozenge and Yindan Pinggan capsules, continuously enriching its "big product" matrix [5]. - The cosmetics subsidiary has implemented a long-term incentive mechanism based on excess profit sharing, successfully launching several products that have achieved over 100 million in sales [5]. Group 2: International Expansion - The company actively participates in national-level events to promote the internationalization of traditional Chinese medicine, including the "Belt and Road" conference and various international trade expos scheduled for 2025 [5]. - The company is involved in multiple international trade fairs, enhancing its global presence and market reach [5]. Group 3: Investment in Health Industry - Since 2024, the company has established three funds, each with a scale of 1 billion, focusing on investments in traditional Chinese medicine, biomedicine, medical devices, and health-related industries [5]. - The company's equity stake in these funds ranges from 20% to 30%, indicating a strong commitment to the health sector [5]. Group 4: Research and Development - In 2024, the company is advancing clinical research on 11 projects related to Pianzaihuang and other traditional Chinese medicine products, laying the groundwork for expanding clinical applications [6]. - The company has a robust pipeline with 14 ongoing new drug projects, including two new traditional Chinese medicine drugs entering clinical trials [6]. - Recent advancements include the completion of Phase I clinical research for a chemical drug and the initiation of Phase II trials for another, showcasing the company's commitment to innovation [6].

Core Viewpoint - The company, Pianzaihuang Pharmaceutical Co., Ltd., reported a solid performance in 2024, achieving a consolidated revenue of approximately 10.788 billion yuan, a year-on-year increase of 7.25%, and a net profit attributable to shareholders of about 2.977 billion yuan, up 6.42% from the previous year [4][5][6]. Group 1: Meeting Procedures and Governance - The 2024 Annual General Meeting (AGM) will be held on June 20, 2025, at 09:00, at the Zhangzhou Xiangjiang Hotel [3]. - The meeting will include a verification of the identity of attendees, and shareholders will have the right to speak, inquire, and vote [2][3]. - Voting will be conducted by registered ballot, with each share representing one vote [2][3]. Group 2: Business Performance - The company achieved a consolidated revenue of approximately 10.788 billion yuan in 2024, representing a 7.25% increase year-on-year [4]. - The net profit attributable to shareholders was about 2.977 billion yuan, reflecting a 6.42% increase compared to the previous year [4]. - The company paid approximately 14 billion yuan in cash dividends, accounting for 50.04% of the net profit attributable to shareholders [9]. Group 3: Honors and Recognition - The company was recognized as one of the "Top 100 Enterprises in Comprehensive Competitiveness of Traditional Chinese Medicine Industry" and received multiple awards for its brand value and cultural heritage [5][6]. - The company ranked first in the market capitalization of the traditional Chinese medicine industry, with a market value exceeding 120 billion yuan [6]. - The company received various awards, including the "2023 Golden Bull Most Investment Value Award" and "2024 Top 20 ESG Competitiveness in Chinese Pharmaceutical Listed Companies" [6]. Group 4: Research and Development - The company is focusing on enhancing its independent innovation capabilities, with ongoing clinical research on 14 new drug projects [12][13]. - The company has established partnerships with over 10 academicians for collaborative projects, aiming to accelerate technological breakthroughs [13]. - The company is actively involved in national key research projects, enhancing its research capabilities in traditional Chinese medicine [13][14]. Group 5: Future Plans - The company plans to increase its new drug projects and clinical research initiatives, aiming to launch 2-3 new drug projects in the coming year [21]. - The company will focus on expanding its market presence in traditional medicine channels and new consumer markets [21]. - The company aims to enhance its brand visibility through new media and targeted marketing strategies [21].

Core Viewpoint - The company achieved revenue and profit growth in 2024 despite rising raw material costs and weak consumer demand, with total revenue of 10.788 billion yuan, a year-on-year increase of 7.25%, and net profit attributable to shareholders of 2.977 billion yuan, a year-on-year increase of 6.42% [1] Group 1: Channel and Brand Development - The company has strengthened its brand and channel construction through various measures, maintaining a gross profit margin of around 45% despite rising costs of natural raw materials [2][3] - The company has optimized its national terminal layout, focusing on filling gaps in the central and western regions, as well as overseas markets, adding 24 national medical clinics and 47 Pi Zai Huang national medicine halls in 2024 [2] - The company expanded its OTC terminal channels by cultivating large single pharmacies and deepening cooperation with major chain pharmacies, achieving coverage of over 100,000 terminal stores and conducting over 5,000 promotional activities [3] Group 2: Innovation and R&D - The company is actively pursuing innovation and modernization of traditional Chinese medicine, with significant research achievements recognized in international journals, enhancing the clinical value of its products [4][5] - The company is advancing new drug development in traditional Chinese medicine, with new drugs for treating anxiety disorders and irritable bowel syndrome entering clinical trials [6] - The company is also exploring potential acquisition targets and has established industry funds to expand its reach in the healthcare sector [6] Group 3: Future Outlook - The company aims to continue its development philosophy of "guarding integrity and innovating" to strengthen its century-old brand and enhance long-term value for shareholders [7]